Paradoxical psoriafisorm reactions due to anti TNF-alpha biologic treatment
DOI:
https://doi.org/10.47196/da.v26i2.2078Keywords:
Psoriasis, Paradoxical psoriasiform reactions, Biologic treatment, Anti-TNF-alphaAbstract
As a consequence of the advance in different medical treatments, like with the use of biologic drugs such as anti-TNF-alpha, there can be seen paradoxical psoriasiform reactions. The paradoxical reactions consist of the exacerbation or the appearance of a new symptom or another disease that, generally, improve with the use of biological agents such as anti-TNF-alpha, drugs have several indications related to the treatment of different inflammatory pathologies, hence, it is crucial that every specialist who prescribes them are aware of this secondary effect.
The aim of this article was to observe and describe the demographic and clinical characteristics of a group of patients with paradoxical psoriasiform reactions; and to compare them with the literature.
References
I. Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev ClinInmunol 2014;10:159-169.
II. Segaert S, Hermans C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol 2017;18:771-787.
III. Fréling E, Baumann C, Cuny JF, Bigard MA,et ál.Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: A 14-year experience. Am J Gastroenterol 2015;110:1186-1196.
IV. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30:700-706.
V. Iborra M, Beltrán B, Bastida G, Aguas M, et ál. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohns Colitis 2011;5:157-161.
VI. Nguyen K, Vleugels RA, Velez NF, Merola J,et ál. Psoriasiform reactions to anti-tumour necrosis factor α therapy. J Clin Rheumatol 2013;19:377-381.
VII. Navarro R, Daudén E. Clinical management of paradoxical psoriasiform reactions during TNF-α therapy. Actas Dermosifiliogr 2014, 105:752-761.
VIII. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, et ál. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-2518.
IX. Conrad C, Di Domizio J, Mylonas A, Belkhodja C, et ál. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018; 9:25.
X. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-108.
XI. Groth D, Perez M, Treat JR, Castelo-Soccio L, et ál. Tumor necrosis factor-αinhibitor-induced psoriasis in juvenile idiopathic arthritis patients. Pediatr Dermatol 2019;36:613-617.
XII. Garcovich S, De Simone C, Genovese G, Benti E,et ál. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol 2019;10:282.
Downloads
Published
Issue
Section
License
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
